Mélanie Tichet
École Polytechnique Fédérale de Lausanne
9 Papers
Mélanie Tichet is an academic researcher from École Polytechnique Fédérale de Lausanne. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells
L. Codarri Deak,V González Nicolini,Masao Hashimoto,Maria Karagianni,Petra C. Schwalie,Laura Lauener,Eleni Maria Varypataki,Marine Richard,Esther Bommer,Johannes Sam,Stefanie Joller,Mario Perro,Floriana Cremasco,Leo Kunz,Emilio Yanguez,Tamara Hüsser,Ramona Schlenker,Marisa Mariani,Vinko Tosevski,Sylvia Herter,Marina Bacac,Inja Waldhauer,Sara Colombetti,Xavier Gueripel,Stephan Wullschleger,Mélanie Tichet,Douglas Hanahan,Haydn T. Kissick,Stéphane Leclair,Anne Freimoser-Grundschober,Stefan Seeber,Volker Teichgräber,Rafi Ahmed,Christian Klein,Pablo Umana +34 more
TL;DR: In this article , a new immunocytokine, PD1-IL2v, was introduced, which overcomes the need for CD25 binding by docking in cis to PD-1.
Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity
Agnieszka Chryplewicz,Julie Scotton,Mélanie Tichet,Anoek Zomer,Ksenya Shchors,Johanna A. Joyce,Krisztian Homicsko,Douglas Hanahan +7 more
TL;DR: In this article , a combination of imipramine with vascular endothelial growth factor (VEGF) pathway inhibitors orchestrates the infiltration and activation of CD8 and CD4 T cells, producing significant therapeutic benefit in several GBM mouse models.
71
Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages.
Mélanie Tichet,Stephan Wullschleger,Agnieszka Chryplewicz,Nadine Fournier,R. Marcone,Annamaria Kauzlaric,Krisztian Homicsko,Laura Codarri Deak,Pablo Umana,Christian Klein,Douglas Hanahan +10 more
TL;DR: In this paper , the effects of the engineered immunocytokine PD1-IL2v in a mouse model of de novo pancreatic neuroendocrine cancer that is resistant to checkpoint and other immunotherapies were evaluated.
69
Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion
Qiqun Zeng,Sadegh Saghafinia,Agnieszka Chryplewicz,Nadine Fournier,Lucine Christe,Yunxuan Xie,Jeremy Guillot,Simge Yucel,Pumin Li,José A. Galván,Eva Karamitopoulou,Inti Zlobec,Dalya Ataca,Fleuriane Gallean,Peng Zhang,José Antonio Rodriguez-Calero,M.L. Rubin,Mélanie Tichet,Krisztian Homicsko,Douglas Hanahan +19 more
TL;DR: Zeng et al. as discussed by the authors found that FMRP-deficient tumors were infiltrated by activated T cells that impaired tumor growth and enhanced survival in mice, and they investigated the functional significance of this broad up-regulation and further assessed its tumor-promoting functions in mouse models of cancer, and evaluated its association with prognosis for human cancer patients.
47
ALK7 Signaling Manifests a Homeostatic Tissue Barrier That Is Abrogated during Tumorigenesis and Metastasis
Iacovos P. Michael,Sadegh Saghafinia,Mélanie Tichet,Nadine Zangger,Ilaria Marinoni,Aurel Perren,Douglas Hanahan +6 more
TL;DR: Mechanistic insights into primary and metastatic tumor development are introduced in the form of a protective barrier that triggers apoptosis in cells that are not "authorized" to proliferate within a particular tissue, by virtue of those cells expressing ALK7 in a tissue microenvironment bathed in its ligand.
39